Welcome to our dedicated page for Repligen SEC filings (Ticker: RGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Repligen Corporation's SEC filings document financial reporting, governance and public-company capital structure for a Nasdaq-listed life sciences company in bioprocessing technology. Recent Form 8-K reports attach earnings releases for quarterly and annual results, financial guidance and non-GAAP measures such as organic revenue, adjusted operating income, adjusted EPS and adjusted EBITDA.
The filing record also includes definitive proxy materials covering board matters, executive compensation and equity awards, along with Form 8-K disclosures on officer appointments, principal accounting officer responsibilities, financial reporting oversight and Sarbanes-Oxley-related infrastructure. Securities registration disclosures identify RGEN common stock, par value $0.01 per share, on the Nasdaq Global Select Market.
Repligen Corporation agreed to acquire BioLife Solutions in a cash-and-stock transaction. Each share of BioLife common stock will be converted into the right to receive $11.25 in cash plus 0.1442 shares of Repligen common stock, subject to an adjustment cap so that total Repligen shares issued do not exceed 19.9% of Repligen’s pre-merger shares outstanding under Nasdaq rules. The deal is structured as a two-step merger, after which BioLife will become a wholly owned subsidiary of Repligen. Closing is targeted for the fourth quarter of 2026, contingent on BioLife stockholder approval, antitrust and other regulatory clearances, SEC effectiveness of a Form S-4 registration statement, Nasdaq listing of the new Repligen shares, and absence of a material adverse effect on either company. Under specified circumstances, including acceptance of a superior proposal, BioLife may owe Repligen a $59 million termination fee. The parties intend the combined mergers to qualify as a tax-free reorganization for U.S. federal income tax purposes. Repligen also furnished a press release with preliminary second-quarter 2026 results and joint communications about the transaction.
Repligen Corporation agreed to acquire BioLife Solutions in a cash-and-stock transaction valuing BioLife at $31.00 per share, or approximately $1.5 billion of enterprise value. Each BioLife share will be converted into $11.25 in cash plus 0.1442 shares of Repligen, with no fractional Repligen shares issued.
The deal, unanimously approved by both boards and expected to close in the fourth quarter of 2026, will be executed via two merger subsidiaries, making BioLife a wholly owned Repligen unit. Closing is subject to BioLife stockholder approval, antitrust clearances including the HSR Act, SEC effectiveness of a Form S-4, Nasdaq listing of new Repligen shares, and customary accuracy of representations and absence of material adverse effects. Under specified circumstances BioLife may owe Repligen a $59 million termination fee, and the merger agreement includes a no-shop with superior-proposal and fiduciary-out exceptions.
Repligen highlights the transaction as expanding its cell therapy tools portfolio and recurring consumables revenue and projects at least $20 million of year-one cost synergies, rising to $30 million in year two, with accretion of at least $0.05 to adjusted EPS in year one and $0.25 in year two. Separately, Repligen reports preliminary second-quarter 2026 revenue growth of 12% reported and 13% organic, while BioLife preliminarily reports $28.5 million in Q2 revenue, up 21% from $23.4 million.
Repligen Corp Chief Financial Officer Jason K. Garland reported selling 530 shares of Common Stock on July 16, 2026 at $150.0000 per share, in a transaction described as a sale in an open market or private transaction. The sale was effected under a Rule 10b5-1 trading plan adopted on December 8, 2025, and he now directly holds 18,829 shares.
Jason K. Garland submitted a Form 144 notice to sell up to 530 shares of common stock through Fidelity Brokerage Services LLC on 07/16/2026, with an aggregate market value of 79500.00 on NASDAQ. These shares were acquired from the issuer via Restricted Stock Vesting on 02/27/2025 as compensation. The notice also lists a prior sale on 06/25/2026 of 733 common shares for 106285.00 within the past three months.
REPLIGEN CORP CFO Jason K. Garland sold a small block of company stock in a pre-planned transaction. On the reported date, he completed an open-market sale of 733 shares of common stock at a price of $145 per share. After this sale, he directly owns 19,359 shares of Repligen common stock. The filing notes that the sale was executed under a Rule 10b5-1 trading plan adopted on December 8, 2025, indicating the transaction was pre-scheduled rather than timed discretionarily.
Repligen Corporation director Martin D. Madaus reported equity awards, not open-market trades. He received 995 restricted stock units, each representing one share of common stock. These units vest on the earlier of May 14, 2027, one year from grant, or the next annual shareholder meeting, and settlement has been deferred until after his board service ends.
He was also granted stock options on 2,239 shares at an exercise price of $103.38 per share, vesting on the same schedule and expiring on May 14, 2036. Following these awards, he directly holds 6,581 common shares and indirectly holds additional shares through a spouse trust with 11 shares and a 2011 revocable trust with 1,800 shares.
Repligen Corporation director Konstantin Konstantinov received new equity awards consisting of restricted stock units and stock options. He was granted 995 restricted stock units, each representing one share of Repligen common stock, bringing his direct common stock holdings to 3,889 shares after the award.
He was also granted stock options covering 2,239 shares of common stock at an exercise price of $103.38 per share, with the options expiring on May 14, 2036. Both the restricted stock units and the option award vest in full on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of shareholders.
Repligen Corporation director Carrie Eglinton Manner reported compensation-related equity awards, not open-market trades. She was granted 995 restricted stock units, each representing a contingent right to receive one share of Repligen common stock. She also received stock options for 2,239 shares at an exercise price of $103.38 per share.
The restricted stock units and the stock option award each vest in full on the earlier of May 14, 2027, one year from the grant date, or the date of Repligen’s next annual meeting of shareholders. Following these grants, she holds 5,461 shares of common stock directly and 2,239 stock options.
Repligen Corp director Rohin Mhatre reported routine equity compensation awards. He received 995 restricted stock units, each representing one share of Repligen common stock, bringing his direct common stock holdings to 5,014 shares after the grant.
He was also granted stock options for 2,239 shares of common stock at an exercise price of $103.38 per share. These options are exercisable starting on May 14, 2027 and expire on May 14, 2036. The restricted stock units and options each vest in full on the earlier of May 14, 2027 or the date of the next annual meeting of shareholders, which has not yet been determined.